− Approval Expands Use of VONVENDI to Include Routine Prophylaxis to Reduce the Frequency of Bleeding Episodes in Adults with…
Highest-ever quarterly net income of $1.385 billion, up 16% YoY, reflects the Company's strong performance Board approves interim dividend of…
Proven efficacy across all three key markers of disease—68% reduction in proteinuria, stabilization of kidney function, and substantial clearance of…